Part 7/8:
Digle's firm, Vulpus Investment Management, is positioning itself to take advantage of opportunities in the biotech sector. He notes that despite the recent downturn in biotech valuations, the potential for significant returns from undervalued companies is ripe for exploitation. With a focus on UK-based biotech firms arising from renowned institutions like Oxford University, Digle believes that now presents a unique moment for investment.
Navigating the inherently challenging nature of biotech investments, Digle emphasizes the need to leverage professional insight while assessing technological innovations and regulatory hurdles.